Citi lowered the firm’s price target on Edwards Lifesciences to $77 from $83 and keeps a Buy rating on the shares. The firm wonders if the recent rally in medical technology shares can hold heading into the Q3 reports. Citi enters earnings season “cautious,” saying Q3 is historically the toughest quarter in MedTech as it brings scrutiny over the 2025 setup and commentary on next year’s numbers “could be a governor of price action in the near-term.” The firm maintains its top picks on Boston Scientific (BSX), GE HealthCare (GEHC) and Insulet (PODD).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Eyes on Fed ahead of expected interest rate cut: Morning Buzz
- Nvidia, ARM initiated: Wall Street’s top analyst calls
- Edwards Lifesciences downgraded to Hold from Buy at Jefferies
- Edwards Lifesciences rumor highlighted in Betaville blog
- Edwards Lifesciences price target lowered to $71 from $82 at Truist